Objectives: The incidence of metastatic vulvar cancer has increased in the United States. We proposed to investigate the clinicopathological factors associated with this concerning trend. Methods: From 2001-2017, incidence rates of vulvar cancers (squamous cell carcinoma, melanoma, adenocarcinoma, sarcoma, and others) were estimated from the United States Cancer Statistics Public Use Database. SEER*Stat and Joinpoint regression programs were used to calculate incidence rate (per 100,000) and average annual percent change (AAPC). Results: Of 76,748 cases of vulvar cancers, 3,486 (4.5%) had metastatic disease. Whites comprised 2,785 (80.5%) cases, followed by Blacks with 353 (10.2%) cases, then Hispanics with 249 (7.2%) cases and Asian/Pacific Islanders with 71 (2.1%) cases. In more recent years, Hispanics had the highest incidence of metastatic vulvar cancer starting after age 70-74 years. In cases 85 years and above, Hispanics had the greatest incidence of metastatic disease at 1.0 per 100,000 compared to Whites (0.82 per 100,000) and Blacks (0.56 per 100,000). Over the course of 16 years, the incidence of metastatic vulvar cancer increased by 3.3% per year (p<0.01) compared to only 0.7% annually for localized disease. Whites had a four-fold higher annual increase in new cases of metastatic disease compared to localized cancers (3.2% vs. 0.8%, p<0.01). Based on regions in the United States, the Northeast and Midwest had higher annual increases in new cases compared to the West at 5.3% and 5.4%, respectively vs. 1%. Based on histology, metastatic squamous cell carcinoma and adenocarcinoma increased at 4.0% and 2.3% per year, respectively. Conclusions: The incidence of metastatic vulvar cancer in US women has increased at 3.3% each year over the last 16 years. Hispanics 85 years and older had the highest incidence compared to other cohorts. The incidence of metastatic vulvar cancer has increased in the United States. We proposed to investigate the clinicopathological factors associated with this concerning trend. From 2001-2017, incidence rates of vulvar cancers (squamous cell carcinoma, melanoma, adenocarcinoma, sarcoma, and others) were estimated from the United States Cancer Statistics Public Use Database. SEER*Stat and Joinpoint regression programs were used to calculate incidence rate (per 100,000) and average annual percent change (AAPC). Of 76,748 cases of vulvar cancers, 3,486 (4.5%) had metastatic disease. Whites comprised 2,785 (80.5%) cases, followed by Blacks with 353 (10.2%) cases, then Hispanics with 249 (7.2%) cases and Asian/Pacific Islanders with 71 (2.1%) cases. In more recent years, Hispanics had the highest incidence of metastatic vulvar cancer starting after age 70-74 years. In cases 85 years and above, Hispanics had the greatest incidence of metastatic disease at 1.0 per 100,000 compared to Whites (0.82 per 100,000) and Blacks (0.56 per 100,000). Over the course of 16 years, the incidence of metastatic vulvar cancer increased by 3.3% per year (p<0.01) compared to only 0.7% annually for localized disease. Whites had a four-fold higher annual increase in new cases of metastatic disease compared to localized cancers (3.2% vs. 0.8%, p<0.01). Based on regions in the United States, the Northeast and Midwest had higher annual increases in new cases compared to the West at 5.3% and 5.4%, respectively vs. 1%. Based on histology, metastatic squamous cell carcinoma and adenocarcinoma increased at 4.0% and 2.3% per year, respectively. The incidence of metastatic vulvar cancer in US women has increased at 3.3% each year over the last 16 years. Hispanics 85 years and older had the highest incidence compared to other cohorts.